PrintThe Burrill Report
The Burrill Report (October 8, 2012): Medtech Ready to Outshine Pharma (.MP3,11.98 Mb)
The medtech industry, long overshadowed by the pharmaceutical industry, is expected to grow at a much faster rate than pharma, according to a new report from EvaluatePharma. EvaluateMedTech World Preview 2018 forecasts growth of 4.4 percent a year to $440 billion by 2018. We spoke to Anthony Raeside, head of research for EvaluatePharma, about the new report, what’s driving growth for the medtech industry, and why Big Pharma may become a big acquirers of some of these companies.
October 05, 2012
http://www.burrillreport.com/article-medtech_ready_to_outshine_pharma.html
MEDTECH
Medtech Ready to Outshine Pharma
Podcast: October 8, 2012[Please login to post comments]
- A Step Closer to Diagnostic Makers Getting Paid for Value
Read More - Wearable Tech Market Has Rich Future
Smart glasses and other wearable devices will be worth more than $1.5B by 2014, finds Juniper. Read More - Sanofi Slashes Price of New Cancer Drug to Respond to Critics
Action reflects new realities for drugmakers. Read More - Takeda Acquires Envoy Therapeutics for $140 Million
Pharma gains access to biotech’s novel technology and preclinical CNS assets. Read More - India Strikes Down Roche Patent
Decision adds to drugmakers’ concerns about protecting sales of patented medicines in the country. Read More - AbbVie Approaches Launch with $14.7 Billion Debt Offering
Startups also enrich their coffers in active week for fundraising. Read More - Pluristem Denies Bloomberg Report that it Hid Patient Death from Investors, Wants Correction
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - New Combinations to Fight Cancer
Data from experiments using 5,000 different pairings of approved drugs will be made available. Read More - Pfizer Wins Approval for Rheumatoid Arthritis Medicine
Xeljanz becomes first RA drug from new class of JAK inhibitors. Read More - Trials Highlight Progress on Cholesterol Drugs
Amgen scores positive data in mid-stage trials, while Roche illuminates a miss. Read More
.gif)
